Literature DB >> 17965862

[Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application].

C H Meyer1, S Mennel, N Eter.   

Abstract

BACKGROUND: Intravitreal injection of vascular endothelial growth factor inhibitors is safe as a standardized procedure. In a retrospective study, we examined the incidence of intraocular inflammation and endophthalmitis when intravitreal Avastin was given on both an outpatient and an inpatient basis. METHODS AND PATIENTS: Two centers treated a total of 1844 patients with intravitreal Avastin injection (IVA), 1.25 mg/0.05 ml. The medication was given under aseptic conditions with a sterile drape and lid speculum and after an incubation of 5% povidone-iodine for 60 s in the conjunctival fornix. Center A performed all applications as an outpatient procedure with no postoperative topical antibiotics. Center B performed all IVAs prior to a 1-day hospital admission and gave topical antibiotics for 3 days. In both centers the patients were told to return to the hospital immediately if visual disturbance, pain, or redness of the eyes was noticed.
RESULTS: Center A did 984 IVAs. Postoperatively no patients had endophthalmitis. On the 2nd postoperative day, two patients developed a mild intraocular uveitis, which was treated with local steroid ointments. Center B did 860 IVAs. Five days after discharge from the hospital, two patients presented with endophthalmitis and underwent vitrectomy when their vision dropped to counting fingers. There was no positive microbiological result of either vitreous probe.
CONCLUSIONS: Although equal treatment guidelines were established, the perioperative hospital admission and postoperative application of topical antibiotic ointment could not reduce the occurrence of mild to severe intraocular endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965862     DOI: 10.1007/s00347-007-1634-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  24 in total

1.  [Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection].

Authors:  M C Dwinger; I Pieper-Bodeewes; N Eter; F G Holz
Journal:  Klin Monbl Augenheilkd       Date:  2005-08       Impact factor: 0.700

2.  Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.

Authors:  F B Aggio; M E Farah; G B de Melo; P A d'Azevedo; A C C Pignatari; A L Höfling-Lima
Journal:  Eye (Lond)       Date:  2007-02-02       Impact factor: 3.775

3.  Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

Authors:  Donald J D'Amico; H N Masonson; Manju Patel; A P Adamis; E T Cunningham; D R Guyer; B Katz
Journal:  Ophthalmology       Date:  2006-04-27       Impact factor: 12.079

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Infectious endophthalmitis after cataract surgery.

Authors:  L Apt; S J Isenberg
Journal:  Br J Ophthalmol       Date:  1994-12       Impact factor: 4.638

6.  [Preoperative infection prophylaxis with 1% polyvidon-iodine solution based on the example of conjunctival staphylococci].

Authors:  C A Binder; H Miño de Kaspar; V Klauss; A Kampik
Journal:  Ophthalmologe       Date:  1999-10       Impact factor: 1.059

7.  Reduction of conjunctival bacterial flora by povidone-iodine, ofloxacin and chlorhexidine in an outpatient setting.

Authors:  Yaniv Barkana; Zina Almer; Ori Segal; Zipora Lazarovitch; Issac Avni; David Zadok
Journal:  Acta Ophthalmol Scand       Date:  2005-06

8.  [Intravitreal triamcinolone acetonide Complication of infectious and sterile endophthalmitis].

Authors:  I Kreissig; R F Degenring; J B Jonas
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

9.  Infectious and noninfectious endophthalmitis after intravitreal bevacizumab.

Authors:  Jost B Jonas; Ulrich H Spandau; Florian Rensch; Stefan Von Baltz; Frank Schlichtenbrede
Journal:  J Ocul Pharmacol Ther       Date:  2007-06       Impact factor: 2.671

10.  Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study.

Authors:  A W Ferguson; J A Scott; J McGavigan; R A Elton; J McLean; U Schmidt; R Kelkar; B Dhillon
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

View more
  11 in total

Review 1.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

2.  [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany].

Authors: 
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

3.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

4.  [Bacterial contamination of needles after intravitreal injection in Paraguay].

Authors:  J C Gines; M M Nentwich; A H Peggy Bedoya; P Cibils; A Esteche; F Laspina; M Samudio; N Fariña; H M de Kaspar
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

5.  Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Authors:  Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman
Journal:  Arch Ophthalmol       Date:  2009-12

6.  Intracameral bevacizumab for rubeotic glaucoma secondary to retinal vein occlusion.

Authors:  Kashif Qureshi; Shahram Kashani; Simon P Kelly
Journal:  Int Ophthalmol       Date:  2008-09-14       Impact factor: 2.031

7.  Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits.

Authors:  Saloomeh Saati; Rajat N Agrawal; Stan Louie; Gerald J Chader; Mark S Humayun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-31       Impact factor: 3.117

8.  Evaluating the safety of intracameral bevacizumab application using oxidative stress and apoptotic parameters in corneal tissue.

Authors:  Ali Akal; Turgay Ulas; Tugba Goncu; Muhammet Emin Guldur; Sezen Kocarslan; Abdullah Taskin; Hatice Sezen; Kudret Ozkan; Omer Faruk Yilmaz; Hakan Buyukhatipoglu
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

9.  [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].

Authors:  K Schmitz; M Maier; C R Clemens; F Höhn; J Wachtlin; F Lehmann; T Bertelmann; K Rüdiger; M Horn; A Bezatis; G Spital; C H Meyer
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

Review 10.  Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone).

Authors:  Tomomi Masuda; Masamitsu Shimazawa; Hideaki Hara
Journal:  Oxid Med Cell Longev       Date:  2017-01-18       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.